Hepatitis G virus infection: Clinical characteristics and response to interferon

Journal of Viral Hepatitis

Volumn 4, Issue 1, 1997, Pages 37-44

  Karayiannis, P ^a   Hadziyannis, S J ^b   Kim, J ^c   Pickering, J M ^a   Piatak, M ^c   Hess, G ^d   Yun, A ^c   McGarvey, M J ^a   Wages, J ^c   Thomas, H C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ATHENS   (Greece)

^c Genelabs Incorporated   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Disease association; Hepatitis G virus; Interferon treatment; Polymerase chain reaction

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; VIRUS RNA;

ARTICLE; BLOOD; FEMALE; FLAVIVIRUS; GENETICS; HEPATITIS B; HEPATITIS C; HUMAN; LIVER TRANSPLANTATION; MALE; MONONUCLEAR CELL; RETROSPECTIVE STUDY; VIROLOGY; VIRUS HEPATITIS;

ANTIVIRAL AGENTS; FEMALE; FLAVIVIRIDAE; HEPATITIS B; HEPATITIS C; HEPATITIS, VIRAL, HUMAN; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; LIVER TRANSPLANTATION; MALE; RETROSPECTIVE STUDIES; RNA, VIRAL;

EID: 0030640892     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1997.00128.x     Document Type: Article

References (20)

1. Alter HJ, Seeff LB. Transfusion-associated hepatitis. In: Zuckerman AJ, Thomas HC, eds. Viral Hepatitis. Edinburgh: Churchill Livingstone, 1993: 467-498.
2. Linnen J, Wages J, Zhang-Keck ZY et al. Molecular cloning and disease association of hepatitis G virus: a new transfusion transmissible agent. Science 1996; 271: 505-508.
3. Simons JN, Pilot-Matias TJ, Leary TP et al. Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Natl Acad Sci USA 1995; 92: 3401-3405.
4. Deinhardt F, Holmes AW, Capps RB, Popper H. Studies on the transmission of human viral hepatitis to marmoset monkeys. Transmission of disease, serial passage and description of liver lesions. J Exp Med 1967; 125: 673-687.
5. Simons JN, Leary TP, Dawson GJ et al. Isolation of novel-like sequences associated with human hepatitis. Nature Med 1995; 1: 564-569.
6. Leary TP, Muerhoff AS, Simons JN et al. Sequence and genomic organisation of GBV-C: a novel member of the flaviviridae associated with human non-A-E hepatitis. J Med Virol 1996; 48: 60-67.
7. Garson JA, Tedder RS, Briggs M et al. Detection of hepatitis C viral sequences in blood donations by 'nested' polymerase chain reaction and prediction of infectivity. Lancet 1990; i: 1419-1422.
8. Karayiannis P, Petrovic LM, Fry M et al. Studies of GB hepatitis agent in tamarins. Hepatology 1989; 9: 186-192.
9. Carman WF, Jacyna MR, Hadziyannis S et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; ii: 588-590.
10. Yoshiba M, Okamoto H, Mishiro S. Detection of the GBV-C hepatitis virus genome in serum from patients with fulminant hepatitis of unknown origin. Lancet 1995; ii: 1131-1132.
11. Kao JH, Chen PJ, Chen DS. GBV-C in the aetiology of fulminant hepatitis. Lancet 1996; i: 120.
12. Lok ASF, Weller IVD, Karayiannis P et al. Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication. Liver 1984; 4: 45-49.
13. Jacyna MR, Thomas HC. Antiviral therapy: Hepatitis B. Br Med Bull 1990; 46: 368-382.
14. Perillo RP. Treatment of chronic hepatitis with interferon: Experience in western countries. Semin Liver Dis 1989; 9: 240-248.
15. Jacyna M, Brooks M, Loke R, Main J, Murray-Lyon I, Thomas HC. Randomised controlled trial of interferon alpha (lymphoblastoid interferon) in chronic non-A, non-B hepatitis. Br Med J 1989; 298: 80-82.
16. Davis G, Balart L, Schiff E et al. Treatment of chronic hepatitis C with recombinant interferon alpha. N Engl J Med 1989; 321: 1506-1510.
17. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow up of patients with chronic hepatitis C with α-interferon. Hepatology 1992; 15: 1013-1016.
18. Karayiannis P, McGarvey MJ. The GB hepatitis viruses. J Viral Hep 1995; 2: 221-226.
19. Zuckerman AJ. Alphabet of hepatitis viruses. Lancet 1996; i: 558-559.
20. Nubling CM, Lower J. GB-C genomes in a high-risk group, in plasma pools, and in intravenous immunoglobulin. Lancet 1996; i: 68.